Sarepta Therapeutics’ Doug Ingram

December 17, 2025

•

1 min read

•

statnews.com

Ingram has taken on unnecessary risks for Duchenne patients, and hasn't served biotech investors well either.

Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some cases in the past, this pick brought me no joy, because the circumstances that earned Ingram this dishonor are tinged with s... [466 chars]

Read Original Article

Source: statnews.com

Visit Source

Share this article

Twitter Facebook

Back to business news